Oregovomab
- Generic Name
- Oregovomab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 213327-37-8
- Unique Ingredient Identifier
- HX101E7L6S
- Background
Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
- Indication
Investigated for use/treatment in ovarian cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 31
- Registration Number
- NCT04620954
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬National Cancer Center Singapore, Singapore, Singapore
Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 13
- Registration Number
- NCT03100006
- Locations
- 🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
- Conditions
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00086632
Clinical Trial for Ovarian Cancer (OvaRex®)
- Conditions
- First Posted Date
- 2002-12-06
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 354
- Registration Number
- NCT00050375
- Locations
- 🇺🇸
St. Jude Medical Center, Fullerton, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Univ. of Texas SW Medical Center at Dallas, Dallas, Texas, United States
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
- Conditions
- First Posted Date
- 2002-04-29
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 102
- Registration Number
- NCT00034372
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇺🇸Parker Hill Oncology & Hematology, Boston, Massachusetts, United States
🇨🇦Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont, Fleurimont, Quebec, Canada
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
- Conditions
- First Posted Date
- 2002-04-24
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00034138
- Locations
- 🇺🇸
Women's Cancer Research Foundation, Miami, Florida, United States
🇺🇸Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.